Furthermore, the CCR5 RO assay correctly identified individuals treated with Leronlimab versus placebo following unblinding, as treated individuals presented at baseline with no CCR5 RO, but then achieved full CCR5 RO on peripheral blood CD4+ T cells at the two follow-up clinical visits, while placebo-treated participants never presented with CCR5 RO (Figure 5B).

In line with the preclinical macaque results, we observed increased frequencies of circulating CCR5+CD4+ T cells following Leronlimab dosing. After Leronlimab initiation, frequencies of CCR5+CD4+ T cells circulating in the peripheral blood in Leronlimab-treated participants were statistically higher than in untreated participants (Figure 5C). Thus, the longitudinal CD4+ T cell CCR5 RO in Leronlimab-treated participants and lack of
measurable CCR5 RO in Leronlimab-untreated participants demonstrates the robustness and sensitivity of the clinical CCR5 RO assay"

Tested against placebo & the companies you mentioned would too have their own Vs. placebo data

Do you think that would be the quickest A-B comparison for look @ how LL did against their placebo compsrisons

& if LL data showed a big difference of CD 4+ Vs theirs, then justification of going frwd further ??....would seem so